This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Insulin-like growth factor binding protein 2 (IGFBP2); integrin α_5 (CD49e); integrin β_1 (CD29); integrin-linked kinase (ILK); NF- κ B	<p>Patient sample and mouse studies suggest inhibiting the integrin/ILK/NF-κB pathway could help treat IGFBP2-driven gliomas. In patient samples, increased expression of integrin α_5, integrin β_1 and ILK all correlated with decreased survival. In a mouse model of IGFBP2-driven glioma, inhibiting Ilk or Nf-κb signaling lowered the incidence of high-grade gliomas compared with no inhibition. Next steps could include evaluating integrin, ILK and NF-κB inhibitors in additional mouse models of IGFBP2-driven gliomas.</p> <p>At least three companies have compounds that inhibit NF-κB signaling in Phase II or earlier testing to treat cancer.</p> <p>SciBX 5(8); doi:10.1038/scibx.2012.196 Published online Feb. 23, 2012</p>	Unpatented; licensing status not applicable	<p>Holmes, K.M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 15, 2012; doi:10.1073/pnas.1120375109</p> <p>Contact: Wei Zhang, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: wzhang@mdanderson.org</p>